Actinium Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Actinium Pharmaceuticals kazanç ve gelirinin sırasıyla yıllık 2.3% ve 63.9% oranında artması tahmin edilirken, EPS'nin yıllık 17.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

2.3%

Kazanç büyüme oranı

17.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	63.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:7AY1 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	7	-53	-23	N/A	5
12/31/2025	15	-37	-20	-34	5
12/31/2024	N/A	-44	-42	-34	5
9/30/2024	0	-41	-35	-35	N/A
6/30/2024	0	-43	-34	-34	N/A
3/31/2024	0	-46	-40	-40	N/A
12/31/2023	0	-49	-47	-47	N/A
9/30/2023	N/A	-50	-48	-48	N/A
6/30/2023	0	-46	-42	-42	N/A
3/31/2023	0	-39	-1	-1	N/A
12/31/2022	1	-33	8	9	N/A
9/30/2022	1	-30	11	11	N/A
6/30/2022	1	-27	11	11	N/A
3/31/2022	1	-25	-21	-21	N/A
12/31/2021	1	-25	-21	-21	N/A
9/30/2021	1	-23	-22	-22	N/A
6/30/2021	1	-22	-22	-21	N/A
3/31/2021	1	-22	-22	-21	N/A
12/31/2020	N/A	-22	-22	-22	N/A
9/30/2020	N/A	-20	-20	-20	N/A
6/30/2020	N/A	-21	-21	-21	N/A
3/31/2020	N/A	-22	-22	-22	N/A
12/31/2019	N/A	-22	-22	-21	N/A
9/30/2019	N/A	-24	-21	-21	N/A
6/30/2019	N/A	-23	-22	-22	N/A
3/31/2019	N/A	-23	-21	-21	N/A
12/31/2018	N/A	-24	-21	-21	N/A
9/30/2018	N/A	-22	-20	-19	N/A
6/30/2018	N/A	-23	N/A	-19	N/A
3/31/2018	N/A	-25	N/A	-22	N/A
12/31/2017	N/A	-27	N/A	-22	N/A
9/30/2017	N/A	-28	N/A	-23	N/A
6/30/2017	N/A	-28	N/A	-22	N/A
3/31/2017	N/A	-28	N/A	-21	N/A
12/31/2016	N/A	-24	N/A	-21	N/A
9/30/2016	N/A	-24	N/A	-21	N/A
6/30/2016	N/A	-22	N/A	-18	N/A
3/31/2016	N/A	-22	N/A	-17	N/A
12/31/2015	N/A	-21	N/A	-19	N/A
9/30/2015	N/A	-20	N/A	-20	N/A
6/30/2015	N/A	-22	N/A	-20	N/A
3/31/2015	N/A	-11	N/A	-18	N/A
12/31/2014	N/A	-25	N/A	-14	N/A
9/30/2014	N/A	-25	N/A	-11	N/A
6/30/2014	N/A	-20	N/A	-8	N/A
3/31/2014	N/A	-27	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 7AY1 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 7AY1 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 7AY1 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 7AY1 şirketinin gelirinin (yıllık 63.9% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 7AY1 şirketinin gelirinin (yıllık 63.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 7AY1 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Actinium Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast breakeven date pushed back to 2026

Forecast breakeven date pushed back to 2026

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Recent updates

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast to breakeven in 2026

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

New major risk - Share price stability

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Forecast to breakeven in 2025

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Forecast to breakeven in 2024

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

Actinium Pharmaceuticals, Inc. Appoints Mark Kubik as Chief Business Officer

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

New 90-day low: €6.75

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA Trial

Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH

Actinium Pharmaceuticals, Inc. Appoints Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs

New 90-day high: €10.30

Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in Its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial

Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory Aml Patients

New 90-day low - €6.59

Actinium Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $24.997873 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin